Tiziana Life Sciences plc

PDMR Dealing

New York/London, 2 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 31 December 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought 12,500 ADSs each representing 5 ordinary shares of nominal value 3p each in the capital of the Company at a price of US$2.79 per ADS, as set out below.

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

As a result of this transaction Mr Cerrone's interests in the underlying ordinary shares of the Company increases from 64,255,925 (47.020%) to 64,318,425 (47.066%). Mr Cerrone's interests in the ordinary shares of the Company are based on a holding of 63,680,404 ordinary shares held by Planwise Limited and voting rights in respect of 638,021 ordinary shares held by Panetta Partners Limited (as shares and via ADSs). Mr Cerrone is considered beneficially interested in the holdings of Panetta Partners Limited and Planwise Limited.

For more information go to http://www.tizianalifesciences.com

Contacts: